More than ten million people worldwide suffer from decompensated cirrhosis, often as a result of severe alcoholic hepatitis (sAH) or other chronic liver diseases. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterised by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need.

The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that improves hepatocyte proliferation through granulocyte colony-stimulating factor (G-CSF) and reduces systemic inflammation by repurposing TAK-242, an antagonist of toll-like receptor 4. We call this novel combinatorial therapy “G-TAK”.

Our vision is to drastically reduce the mortality rate of end-stage liver disease within the 5 years of the project and thereafter and to improve the prognosis, life expectancy, and quality of life of patients who suffer from decompensated cirrhosis.

Launched to support dissemination and impact for A-TANGO, the Liver Health Helix is an international Open Innovation community of specialists in the fields of liver disease, in particular, from cirrhosis, hepatology, drug manufacturing, bioinformatics, and related disciplines. The Helix supports A-TANGO project's ambition to improve the therapeutic options by shaping new treatments.

The First Liver Health Helix event will act as a platform for sharing research results and experiences in drug development challenges in clinical trials and fostering potential collaborations between attendees. 

The event aims to bring together industry end-users, investors and researchers to discover and discuss common challenges in drug development during clinical trials and ideas for overcoming said challenges.

Key Event Objectives

• To communicate and disseminate A-Tango project’s results to a broader audience
• To connect industry and the scientific community to pinpoint drug development challenges in clinical trials collaboratively
• To showcase Liver Health Helix – a virtual collaboration community on the Crowdhelix platform for collaboration in the field.

 Join us to:

• Share and learn about drug development challenges in clinical trials from the perspective of the industry
• Create new networks between industry end-users, investors, and the research community
• Explore the Liver Health Helix and its potential benefits for acceleration research